Marine Drug Research in China: Selected Papers from the 15-NASMD Conference
The Book covers this whole field, from the discovery of structurally new and bioactive natural products (including biomacromolecules), from marine macro-/micro-organisms, to the pharmacodynamics, pharmacokinetics, metabolisms, and mechanisms of marine-derived lead compounds, both in vitro and in viv...
Saved in:
Other Authors: | , , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_92038 | ||
005 | 20220916 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220916s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-4570-7 | ||
020 | |a 9783036545691 | ||
020 | |a 9783036545707 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-4570-7 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Zhou, Xuefeng |4 edt | |
700 | 1 | |a Luo, Xiaowei |4 edt | |
700 | 1 | |a Liu, Yonghong |4 edt | |
700 | 1 | |a Zhou, Xuefeng |4 oth | |
700 | 1 | |a Luo, Xiaowei |4 oth | |
700 | 1 | |a Liu, Yonghong |4 oth | |
245 | 1 | 0 | |a Marine Drug Research in China: Selected Papers from the 15-NASMD Conference |
260 | |a Basel |c 2022 | ||
300 | |a 1 electronic resource (512 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a The Book covers this whole field, from the discovery of structurally new and bioactive natural products (including biomacromolecules), from marine macro-/micro-organisms, to the pharmacodynamics, pharmacokinetics, metabolisms, and mechanisms of marine-derived lead compounds, both in vitro and in vivo, along with the synthesis and/or structural optimization of marine-derived lead compounds and their structure-activity relationships. Taken together, this Special Issue reprint not only provides inspiration for the discovery of marine-derived novel bioactive compounds, but also sheds light on the further research and development of marine candidate drugs. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a Antarctic krill (Euphausia superba) | ||
653 | |a peptide | ||
653 | |a antioxidant activity | ||
653 | |a stability | ||
653 | |a oyster | ||
653 | |a plasma | ||
653 | |a peptidome | ||
653 | |a antimicrobial peptides | ||
653 | |a cytotoxicity | ||
653 | |a actinomycete | ||
653 | |a piericidins | ||
653 | |a absolute configuration | ||
653 | |a Pestalotiopsis heterocornis | ||
653 | |a heterocornols | ||
653 | |a anti-inflammatory activity | ||
653 | |a sponge-derived fungus | ||
653 | |a sclerotides | ||
653 | |a lipodepsipeptide | ||
653 | |a Aspergillus sclerotiorum | ||
653 | |a nasopharyngeal carcinoma | ||
653 | |a AChE inhibitory | ||
653 | |a vascular endothelial cell | ||
653 | |a flavonoid | ||
653 | |a oxidized low-density lipoprotein | ||
653 | |a Nrf2 | ||
653 | |a apoptosis | ||
653 | |a butyrolactone I | ||
653 | |a food allergy | ||
653 | |a metabolism | ||
653 | |a pharmacokinetics | ||
653 | |a actinomycin X2 | ||
653 | |a microbial pigments | ||
653 | |a dyeing | ||
653 | |a silk | ||
653 | |a antibacterial properties | ||
653 | |a PD-L1 | ||
653 | |a virtual screening | ||
653 | |a pharmacophore modeling | ||
653 | |a ADME | ||
653 | |a molecular dynamics | ||
653 | |a xanthones | ||
653 | |a ascidian-derived fungus | ||
653 | |a Diaporthe sp. | ||
653 | |a anti-glioma activity | ||
653 | |a antiaging | ||
653 | |a Sonneratia apetala | ||
653 | |a signaling pathway | ||
653 | |a Caenorhabditis elegans | ||
653 | |a mutants | ||
653 | |a coral-derived fungi | ||
653 | |a Aspergillus hiratsukae | ||
653 | |a meroterpenoids | ||
653 | |a antibacterial activity | ||
653 | |a cytotoxic activity | ||
653 | |a deep-sea-derived fungus | ||
653 | |a Aspergillus puniceus | ||
653 | |a isoquinoline alkaloid | ||
653 | |a protein tyrosine phosphatase inhibitor | ||
653 | |a antibacterial | ||
653 | |a Aspergillus sp. | ||
653 | |a geodin | ||
653 | |a semisynthesize | ||
653 | |a insecticidal activity | ||
653 | |a Arca inflata | ||
653 | |a antitumor peptide | ||
653 | |a MAPK signaling | ||
653 | |a calmodulin | ||
653 | |a colorectal cancer | ||
653 | |a methicillin-resistant Staphylococcus aureus | ||
653 | |a actinomycin D | ||
653 | |a Streptomyces parvulus | ||
653 | |a mechanism | ||
653 | |a mangrove endophytic Pestalotiopsis | ||
653 | |a Sdy-1 | ||
653 | |a antitumor activity | ||
653 | |a Wnt signaling | ||
653 | |a β-catenin | ||
653 | |a eremophilane sesquiterpenoids | ||
653 | |a mangrove-derived fungus | ||
653 | |a Penicillium sp. | ||
653 | |a Oceanapia | ||
653 | |a sponge | ||
653 | |a secondary metabolites | ||
653 | |a biological activities | ||
653 | |a drug design | ||
653 | |a anticancer | ||
653 | |a cyclic pentapeptide | ||
653 | |a galaxamide analogues | ||
653 | |a skipjack tuna (Katsuwonus pelamis) muscle | ||
653 | |a angiotensin-I-converting enzyme (ACE) peptide | ||
653 | |a molecular docking | ||
653 | |a nitric oxide (NO) | ||
653 | |a endothelin-1 (ET-1) | ||
653 | |a Trichoderma longibrachiatum | ||
653 | |a sesquiterpene glycoside | ||
653 | |a antimicrobial activity | ||
653 | |a marine fungi | ||
653 | |a Aspergillus unguis | ||
653 | |a depsides | ||
653 | |a depsidones | ||
653 | |a osteoclast differentiation | ||
653 | |a soft-coral-derived fungus | ||
653 | |a pyranodipyran derivatives | ||
653 | |a tyrosyl DNA phosphodiesterase 1 inhibitory activities | ||
653 | |a fluorescent properties | ||
653 | |a butenolides | ||
653 | |a enantiomers | ||
653 | |a Aspergillus terreus | ||
653 | |a pancreatic lipase | ||
653 | |a NAFLD | ||
653 | |a fucoxanthin | ||
653 | |a adenosine monophosphate-activated protein kinase (AMPK) | ||
653 | |a nuclear factor erythroid-2-related factor 2-mediated (Nrf2) | ||
653 | |a Toll-like receptor 4-mediated (TLR4) | ||
653 | |a Aspergillus flavipes HN4-13 | ||
653 | |a emodin | ||
653 | |a macroporous resin XAD-16 | ||
653 | |a adsorption kinetics and isotherms | ||
653 | |a enrichment | ||
653 | |a tetramic acid derivatives | ||
653 | |a deep-sea fungus | ||
653 | |a clavipitacae | ||
653 | |a Lecanicillium fusisporum | ||
653 | |a chronic kidney disease | ||
653 | |a fucoidan | ||
653 | |a cognitive dysfunction | ||
653 | |a neuroinflammation | ||
653 | |a oxidative stress | ||
653 | |a GSK3β-Nrf2-HO-1 signaling | ||
653 | |a microglial polarization | ||
653 | |a deep-sea actinomycetes | ||
653 | |a aromatic acids | ||
653 | |a oximes | ||
653 | |a antihyperlipidemic | ||
653 | |a phycocyanin | ||
653 | |a microbiota | ||
653 | |a transcriptome | ||
653 | |a IL-17 pathway | ||
653 | |a Hahella | ||
653 | |a prodiginine | ||
653 | |a chejuenlide | ||
653 | |a genome mining | ||
653 | |a LC-MS/MS | ||
653 | |a CDK4/6 | ||
653 | |a marine compounds | ||
653 | |a pharmacophore construction | ||
653 | |a ADMET | ||
653 | |a mm-pbsa | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5911 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/92038 |7 0 |z DOAB: description of the publication |